CN102516392A - Cancer-targeted super antigen fusion protein, and preparation method and application thereof - Google Patents
Cancer-targeted super antigen fusion protein, and preparation method and application thereof Download PDFInfo
- Publication number
- CN102516392A CN102516392A CN2011103787994A CN201110378799A CN102516392A CN 102516392 A CN102516392 A CN 102516392A CN 2011103787994 A CN2011103787994 A CN 2011103787994A CN 201110378799 A CN201110378799 A CN 201110378799A CN 102516392 A CN102516392 A CN 102516392A
- Authority
- CN
- China
- Prior art keywords
- see
- seq
- nucleotide sequence
- fusion rotein
- coding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 95
- 231100000617 superantigen Toxicity 0.000 title claims abstract description 76
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 title claims abstract description 75
- 201000011510 cancer Diseases 0.000 title claims abstract description 62
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 108020001507 fusion proteins Proteins 0.000 title abstract description 16
- 102000037865 fusion proteins Human genes 0.000 title abstract description 10
- 230000003993 interaction Effects 0.000 claims abstract description 19
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims abstract description 17
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 15
- 108090001053 Gastrin releasing peptide Proteins 0.000 claims abstract description 14
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 13
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims abstract description 13
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract description 13
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000147 enterotoxin Substances 0.000 claims abstract description 12
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 5
- 230000005907 cancer growth Effects 0.000 claims abstract description 5
- 230000004927 fusion Effects 0.000 claims description 86
- 239000002773 nucleotide Substances 0.000 claims description 51
- 125000003729 nucleotide group Chemical group 0.000 claims description 51
- 150000001413 amino acids Chemical class 0.000 claims description 49
- 235000001014 amino acid Nutrition 0.000 claims description 36
- 229940088597 hormone Drugs 0.000 claims description 25
- 239000005556 hormone Substances 0.000 claims description 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 18
- 229920001184 polypeptide Polymers 0.000 claims description 16
- 102000004127 Cytokines Human genes 0.000 claims description 13
- 108090000695 Cytokines Proteins 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 102100036519 Gastrin-releasing peptide Human genes 0.000 claims description 11
- 102400001320 Transforming growth factor alpha Human genes 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 5
- PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 3
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims description 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 230000035772 mutation Effects 0.000 abstract description 24
- 101710098940 Pro-epidermal growth factor Proteins 0.000 abstract description 12
- 230000004071 biological effect Effects 0.000 abstract description 9
- 230000001093 anti-cancer Effects 0.000 abstract description 5
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 108020003175 receptors Proteins 0.000 abstract description 3
- 102000005962 receptors Human genes 0.000 abstract description 3
- 239000003446 ligand Substances 0.000 abstract description 2
- 230000002018 overexpression Effects 0.000 abstract description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 abstract 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000036647 reaction Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 58
- 210000001744 T-lymphocyte Anatomy 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 22
- 238000000034 method Methods 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 239000012634 fragment Substances 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 16
- 239000000370 acceptor Substances 0.000 description 15
- 108010074328 Interferon-gamma Proteins 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 108091008146 restriction endonucleases Proteins 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 230000004614 tumor growth Effects 0.000 description 9
- 102100037850 Interferon gamma Human genes 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 244000309466 calf Species 0.000 description 7
- 238000001712 DNA sequencing Methods 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 201000007270 liver cancer Diseases 0.000 description 6
- 208000014018 liver neoplasm Diseases 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 206010039491 Sarcoma Diseases 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000012151 immunohistochemical method Methods 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000004153 renaturation Methods 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102100035194 Placenta growth factor Human genes 0.000 description 3
- 108010087786 Prolactin-Releasing Hormone Proteins 0.000 description 3
- 102100028850 Prolactin-releasing peptide Human genes 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000000139 costimulatory effect Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000002224 dissection Methods 0.000 description 3
- 231100000655 enterotoxin Toxicity 0.000 description 3
- 230000012447 hatching Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 210000003000 inclusion body Anatomy 0.000 description 3
- 210000005265 lung cell Anatomy 0.000 description 3
- 239000002877 prolactin releasing hormone Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000452 restraining effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 108010002913 Asialoglycoproteins Proteins 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 2
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 101150084418 EGF gene Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 102000004862 Gastrin releasing peptide Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 2
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 2
- 102400001369 Heparin-binding EGF-like growth factor Human genes 0.000 description 2
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 2
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- RRVIAQKBTUQODI-UHFFFAOYSA-N Methabenzthiazuron Chemical compound C1=CC=C2SC(N(C)C(=O)NC)=NC2=C1 RRVIAQKBTUQODI-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 108010003044 Placental Lactogen Proteins 0.000 description 2
- 102100024819 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 101710142969 Somatoliberin Proteins 0.000 description 2
- 102000005157 Somatostatin Human genes 0.000 description 2
- 108010056088 Somatostatin Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
- 230000009831 antigen interaction Effects 0.000 description 2
- 230000008106 antitumoral immune reaction Effects 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940015047 chorionic gonadotropin Drugs 0.000 description 2
- 229940041967 corticotropin-releasing hormone Drugs 0.000 description 2
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
- 229960000553 somatostatin Drugs 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 101710178133 Exotoxin type C Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 101150026259 GRP gene Proteins 0.000 description 1
- 102100030671 Gastrin-releasing peptide receptor Human genes 0.000 description 1
- 101710120928 Gastrin-releasing peptide receptor Proteins 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 102100033851 Gonadotropin-releasing hormone receptor Human genes 0.000 description 1
- 101710082444 Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 230000010740 Hormone Receptor Interactions Effects 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 1
- 101710200814 Melanotropin alpha Proteins 0.000 description 1
- 102400000058 Neuregulin-1 Human genes 0.000 description 1
- 108090000556 Neuregulin-1 Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000004576 Placental Lactogen Human genes 0.000 description 1
- 239000000381 Placental Lactogen Substances 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 108090000794 Streptopain Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 101710182532 Toxin a Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000002070 Transferrins Human genes 0.000 description 1
- 108010015865 Transferrins Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108060002566 ephrin Proteins 0.000 description 1
- 102000012803 ephrin Human genes 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940074383 interleukin-11 Drugs 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 108010066925 sleep-promoting factor B Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 1
- SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a cancer-targeted super antigen fusion protein, and a preparation method and application thereof. The fusion protein contains: a) a ligand which promotes the growth of cancer cells and interacts with a cancer cell overexpression receptor; and b) super antigen Staphylococcus aureus enterotoxin E and mutants thereof which can cause anti-cancer immunologic reaction, wherein the Staphylococcus aureus enterotoxin E is abbreviated to SEE, and the mutants of the Staphylococcus aureus enterotoxin E are abbreviated to SEE-X, and X=1-3. Compared with SEA, the super antigen SEE disclosed by the invention is more stable; and SEE-1, SEE-2 and SEE-3, the mutants of SEE subjected to large-scale multi-point mutation reconstruction, reduce the interaction with MHC. Thus, the fusion protein composed of the SEE mutants and TGF-alpha, EGF, VEGF, GnRH or GRP indicates very high anti-cancer and anti-tumor biological activity.
Description
Technical field
The present invention relates to a kind of superantigen fusion rotein and Preparation method and use, particularly relate to a kind of cancer-targeted super antigen and mutant fusion protein thereof and Preparation method and use.
Background technology
The superantigen fusion rotein is applied to the drug research of cancer, for example cytokine and superantigen constructed fusion rotein (one Chinese patent application numbers 200310109829.7, " a kind of can in order to the super antigen fusion protein and the working method thereof of anticancer therapy "; One Chinese patent application numbers 201010118438.1, " cytokine-superantigen fusion rotein is in the application of preparation solid tumor resisting medicine "; One Chinese patent application numbers 201010585818.6, " cytokine-superantigen fusion rotein is in the application of preparation cancer therapy drug "; PLoSOne 6; E16642; 2011), hormone and superantigen constructed fusion rotein (one Chinese patent application number 200510078775.1 " cancer-targeted super antigen fusion protein and working methods thereof ") and antibody and superantigen constructed fusion rotein (Proc Natl Acad Sci USA; 91,8945-8949,1994; Proc Natl Acad Sci USA; 92; 9791-9795; 1995), the hormone in cytokine in cytokine-superantigen fusion rotein and hormone-superantigen fusion rotein be through with cancer cells on great expression cytokine receptor and hormone receptor interaction and fusion rotein is navigated on the cancer cells and the CDCC of another part of fusion rotein to be superantigen can induce t cell responses of attacking cancer cells.
Above-mentioned superantigen is staphylococcus aureus toxin A (Staphylococcal-enterotoxin A; SEA); It can produce the spinoff of the lymphocytic reaction of general, and research (Proc Natl Acad Sci USA, 94 are arranged; 2489-2494,1997) it has been carried out the transformation of a point mutation.In addition, it is reported SEA itself also unstable (J Biol Chem, 275,1665-1672,2000).Improve the anticancer effect of superantigen fusion rotein, can select the new superantigen of thinking except SEA.
In addition; Activated have the material that utilize to be worth for example compound, nucleic acid, polypeptide etc. can improve its activity or utility value through the structure of transforming them; With the enzyme is example, can remove or means such as increase improve the catalytic activity of enzyme, heat-resisting, low temperature resistant, acidproof, alkaline-resisting, organic solvent-resistant etc. through the displacement of extensive multipoint mutation, fragment, amino acid.So, expect to create the higher superantigen of biological activity through to the large-scale point mutation transformation of superantigen.
Summary of the invention
The objective of the invention is to overcome deficiency of the prior art, provide biological activity higher a kind of cancer-targeted super antigen fusion rotein.
Second purpose of the present invention provides a kind of preparation method of superantigen fusion rotein.
The 3rd purpose of the present invention provides a kind of purposes of superantigen fusion rotein.
Technical scheme of the present invention is summarized as follows:
A kind of cancer-targeted super antigen fusion rotein, this fusion rotein contains:
A) promote growth of cancer cells and with the part of cancer cells over-expresses acceptor interaction, said part is the polypeptide of cytokine, hormone or the non-hormone of the non-antibody acellular factor;
B) can cause antitumor immune reaction the superantigen staphylococcus aureus enterotoxin E (Staphylococcal-enterotoxin E, SEE) and two mutants, said staphylococcus aureus enterotoxin E is represented with the SEE that abridges; The two mutants of said staphylococcus aureus enterotoxin E is represented said X=1-3 with abbreviation SEE-X.
Said cytokine is selected from transforminggrowthfactor-(the Transforming growth factor-α that is abbreviated as TGF-α; TGF-α), be abbreviated as Urogastron (the Epidermal growth factor of EGF; EGF), be abbreviated as VEGF vascular endothelial growth factor (Vascular endothelial cell growth factor, VEGF); Said hormone be selected from the gonadotropin releasing hormone of being abbreviated as GnRH (Gonadotropin-releaslng hormone, GnRH); The polypeptide of the non-hormone of the said non-antibody acellular factor be selected from the gastrin releasing peptide of being abbreviated as GRP (Gastrin-releasing peptide, GRP).
Said SEE is the aminoacid sequence shown in the SEQ ID No.2; Said SEE-1 is the aminoacid sequence shown in the SEQ ID No.4; Said SEE-2 is the aminoacid sequence shown in the SEQ ID No.6; Said SEE-3 is the aminoacid sequence shown in the SEQ ID No.8.
Said SEE-1 is that the one or more amino acid on 20,21,24,27,34,39,40,1,42,44,49,74,75,78,79,81,83,84,217,220,222,223,225,227 on the SEE are replaced.
Said SEE-2 is that the one or more amino acid on 20,21,24,27,34,35,39,40,41,42,44,45,46,49,74,75,78,79,81,83,84,188,190,217,219,220,222,223,224,225,227 on the SEE are replaced.
Said SEE-3 is that the one or more amino acid on 20,21,24,27,34,35,36,39,40,41,42,44,45,46,49,62,74,75,77,78,79,81,83,84,188,190,217,218,219,220,221,222,223,224,225,227 on the SEE are replaced.
Said this fusion rotein is: by the TGF-α-SEE shown in the SEQ ID No.10; By the EGF-SEE shown in the SEQ ID No.18; By the VEGF-SEE shown in the SEQ ID No.26; By the GnRH-SEE shown in the SEQ ID No.34; By the GRP-SEE shown in the SEQ ID No.42; By the TGF-α-SEE-1 shown in the SEQ ID No.12; By the EGF-SEE-1 shown in the SEQ ID No.20; By the VEGF-SEE-1 shown in the SEQ ID No.28; By the GnRH-SEE-1 shown in the SEQ ID No.36; By the GRP-SEE-1 shown in the SEQ ID No.44; By the TGF-α-SEE-2 shown in the SEQ ID No.14; By the EGF-SEE-2 shown in the SEQ ID No.22; By the VEGF-SEE-2 shown in the SEQ ID No.30; By the GnRH-SEE-2 shown in the SEQ ID No.38; By the GRP-SEE-2 shown in the SEQ ID No.46; By the TGF-α-SEE-3 shown in the SEQ ID No.16; By the EGF-SEE-3 shown in the SEQ ID No.24; By the VEGF-SEE-3 shown in the SEQ ID No.32; By the GnRH-SEE-3 shown in the SEQ ID No.40; Or by the GRP-SEE-3 shown in the SEQ ID No.48.
Recombinant vectors contains the nucleotide sequence of coding claim 7 said fusion rotein, and said nucleotides sequence is classified the nucleotide sequence SEQ ID No.9 of coding SEQ ID No.10 as; The nucleotide sequence SEQ ID No.11 of coding SEQ ID No.12; The nucleotide sequence SEQ ID No.13 of coding SEQ ID No.14; The nucleotide sequence SEQ ID No.15 of coding SEQ ID No.16; The nucleotide sequence SEQ ID No.17 of coding SEQ ID No.18; The nucleotide sequence SEQ ID No.19 of coding SEQ ID No.20; The nucleotide sequence SEQ ID No.21 of coding SEQ ID No.22; The nucleotide sequence SEQ ID No.23 of coding SEQ ID No.24; The nucleotide sequence SEQ ID No.25 of coding SEQ ID No.26; The nucleotide sequence SEQ ID No.27 of coding SEQ ID No.28; The nucleotide sequence SEQ ID No.29 of coding SEQ ID No.30; The nucleotide sequence SEQ ID No.31 of coding SEQ ID No.32; The nucleotide sequence SEQ ID No.33 of coding SEQ ID No.34; The nucleotide sequence SEQ ID No.35 of coding SEQ ID No.36; The nucleotide sequence SEQ ID No.37 of coding SEQ ID No.38; The nucleotide sequence SEQ ID No.39 of coding SEQ ID No.40; The nucleotide sequence SEQ ID No.41 of coding SEQ ID No.42; The nucleotide sequence SEQ ID No.43 of coding SEQ ID No.44; The nucleotide sequence SEQ ID No.45 of coding SEQ ID No.46; Or shown in the nucleotide sequence SEQ IDNo.47 of coding SEQ ID No.48.
A kind of preparation method of cancer-targeted super antigen fusion rotein cultivates the host cell that contains above-mentioned recombinant vectors, collects and expresses a kind of cancer-targeted super antigen fusion rotein.
A kind of cancer-targeted super antigen fusion rotein is in the application of the medicine of preparation treatment cancer and anti entity tumour.
Advantage of the present invention:
Superantigen SEE is than more stable (the J Biol Chem of SEA; 275; 1665-1672; 2000), and reduced the interaction with MHC, so the fusion rotein of being made up of SEE two mutants and TGF-α, EGF, VEGF, GnRH or GRP shows very high anticancer and anti-tumor bioactivity through improved SEE two mutants SEE-1, SEE-2 and the SEE-3 of extensive multipoint mutation.
Description of drawings
Fig. 1 is that TGF-α and SEE or SEE two mutants are formed fusion rotein and suppressed the S180 tumor growth, expression be tumor growth curve with the mouse dissection after tumor weight.
Fig. 2 is that EGF and SEE or SEE two mutants are formed fusion rotein and suppressed the S180 tumor growth, expression be tumor growth curve with the mouse dissection after tumor weight.
Fig. 3 is that VEGF and SEE or SEE two mutants are formed fusion rotein and suppressed the S180 tumor growth, expression be tumor growth curve with the mouse dissection after tumor weight.
Fig. 4 utilizes the detected T cell of immunohistochemical methods, and brown point is the T cell.(among the figure: 4-1 is TGF-α-SEE-3 administration group; 4-2 is an EGF-SEE-3 administration group; 4-3 is a VEGF-SEE-3 administration group)
Fig. 5 utilizes the detected interferon-by T emiocytosis of immunohistochemical methods (IFN-γ), and brown part is IFN-γ.(among the figure: 5-1 is TGF-α-SEE-3 administration group; 5-2 is an EGF-SEE-3 administration group; 5-3 is a VEGF-SEE-3 administration group)
Fig. 6 is that 6nRH and SEE or SEE two mutants are formed fusion rotein and killed and wounded Hep G2 liver cancer cell.
Fig. 7 is that GRP and SEE or SEE two mutants are formed fusion rotein and killed and wounded the A549 lung carcinoma cell.
The cancer cells of being attacked by the T cell that Fig. 8 shows, maxicell is a cancer cells, minicell is the T cell.(among the figure: 8-1 is the GnRH-SEE-3 group; 8-2 is the GRP-SEE-3 group)
Embodiment
Strategic thought of the present invention is following:
Though can improve the performance of SEA through a point mutation, seek one and then can increase substantially the biological activity of superantigen than better superantigen of SEA and the structure construction that carries out proteic multipoint mutation, obtain better cancer therapy effect.
The superantigen of streptococcus aureus origin has SEA, SEB, SEC, SED, SEF, SEG, SEH, SEI, SEJ etc., and they structurally have certain similarity (Infect Immun, 66; 3337-3348,1998), so the also reference each other of their space structure; SEA (EMBO J for example; 14,3292-3301,1995; J Biol Chem, 271,32212-32216,1996; J Mol Biol, 269,270-280,1997; Structure, 10,1619-1626,2002), SEB and SEC (Nature, 368,711-718,1994; Nature, 384,188-192,1996; J Mol Biol, 277,61-79,1998; Structure, 11,1151-1161,2003), SHE (EMBO J, 20,3306-3312,2001; J Mol Biol, 302,527-537,2000), and other relevant document (Nature, 346,471-473,1990; Infect Immun, 59,2126-2134,1991; J Exp Med, 175,415-424,1992; Proc Natl Acad Sci USA, 89,7727-7731,1992; J Exp Med, 177,175-184,1993; Infect Immun, 61,2059-2068,1993; J Biol Chem, 275,1665-1672,2000; Trends Microbiol, 8,369-375,2000; Immunity, 14,331-344,2001; Clin Exp Immunol, 133,299-306,2003; J Mol Biol, 333,893-905,2003; J Biol Chem, 278,50412-50421,2003; Scand J Immunol, 59,345-355,2004; Semin Immunol, 19,262-271,2007), superantigen comprise the 20-27 amino acid fragment among SEE and the SEA be considered to the T cell on TCR interact, thereby activated T cell; Amino acid fragments such as 34-49,74-84,187-190 and 217-227 are considered to interact with histocompatibility antigen MHC.Can seek a biological activity that improves it than the more effective superantigen of SEA and through large-scale multipoint mutation through these information.
At first the present invention selects SEE, and it is compared with SEA has very big similarity but than SEA more stable (J Biol Chem, 275,1665-1672,2000), in the aminoacid sequence of SEE, can introduce extensive multipoint mutation, and the foundation of point mutation is:
1. strengthen the binding ability of TCR, the effect of strengthening superantigen and TCR just can improve the ability of superantigen inducing T cell, can consider to be employed in the amino acid on the SEA same position here.
2. reduce the binding ability with histocompatibility antigen MHC, the interaction of superantigen SEE and histocompatibility antigen MHC such as synantibody are similar with the polypeptide antigen interaction, are the complementary interactions.The mode of its effect is:
1) interaction of polare Aminosaeren, i.e. the interaction of acidic amino acid in the superantigen and the basic aminoacids in the histocompatibility antigen, the perhaps interaction of basic aminoacids in the superantigen and the acidic amino acid in the histocompatibility antigen;
2) interaction of nonpolar hydrophilic amino acid, i.e. interaction between the nonpolar hydrophilic amino acid in superantigen and the histocompatibility antigen;
3) interaction of nonpolar hydrophobic amino acid, i.e. interaction between the nonpolar hydrophobic amino acid in superantigen and the histocompatibility antigen;
4) the amino acid whose interaction of 1-3 needs suitable space above, and promptly amino acid whose side chain lengths is suitable, the people for a change interactional amino acid whose length also can reduce these amino acid whose interactions.
So; Through changing the amino acid whose character of superantigen and histocompatibility antigen interaction zone, for example change in the superantigen and interactional amino acid whose polarity of histocompatibility antigen and length etc. can reduce or weaken the interaction between superantigen and the histocompatibility antigen.
Though disclosed the position of point mutation among the present invention embodiment 1 below, in fact can also on the position on these positions or its next door, introduce the amino acid of other similar physico-chemical property, also can obtain similar result.
As another part of modified version superantigen fusion rotein be selected from the cancer cells surface on the interactional part of acceptor (Receptor) (Ligand) of great expression; The polypeptide of cytokine, hormone or the non-hormone of the non-antibody acellular factor for example; In the present invention; Cytokine is TGF-α, EGF or VEGF, hormone GnRH, and the polypeptide of the non-hormone of the non-antibody acellular factor is GRP.
Superantigen is the superantigen SEE of staphylococcus aureus enterotoxin E, shown in SEQ ID No.2;
The SEE two mutants of superantigen for transforming through multipoint mutation, wherein two mutants SEE-1 is shown in the SEQ ID No.4, and two mutants SEE-2 is shown in the SEQ ID No.6, and two mutants SEE-3 is shown in the SEQ ID No.8;
Described multipoint mutation occurs in 20,21,24,27,34,35,36,39,40,41,42,44,45,46,49,62,74,75,77,78,79,81,83,84,188,190,217,218,219,220,221,222,223,224,225,227;
The amino acid of described multipoint mutation is, on 20, and Arg → Gly; On 21, Asn → Thr; On 24, Ser → Gly; On 27, Arg → Lys; On 34, Glu → Ser or Glu → Ala; On 35, Lys → Ser; On 36, Ala → Gly; On 39, Glu → Ser; On 40, Asn → Ser or Asn → Ala; On 41, Lys → Glu; On 42, Glu → Lys; On 44, Asp → Ala or Asp → Ser; On 45, Asp → Ala; On 46, Gln → Ser; On 49, Glu → Thr or Glu → Ser; On 62, Pro → Ser; On 74, Lys → Thr or Lys → Ser; On 75, Asp → Ala or Asp → Thr; On 77, Thr → Ser; On 78, Asn → Ser; On 79, Lys → Glu; On 81, Lys → Glu; On 83, Lys → Ser; On 84, Lys → Ser or Lys → Thr; On 188, Ser → Thr; On 190, Glu → Thr; On 217, Lys → Thr or Lys → Ser; On 218, Thr → Ser; On 219, Ile → Leu; On 220, Asn → Ser; On 221, Ser → Thr; On 222, Glu → Thr or Glu → Ser; On 223, Asn → Ser; On 224, Leu → Ile; On 225, His → Ser; On 227, Asp → Ser.
The part of utilization of the present invention and cancer cells acceptor interaction-modified version super antigen fusion protein; Wherein with the part of cancer cells acceptor interaction for example the polypeptide of cytokine, hormone or the non-hormone of the non-antibody acellular factor can fused protein be navigated on the tumour cell; The modified version superantigen then causes more powerful antitumor immune reaction around tumour cell; Be the cell-mediated CDCC that relies on of superantigen (Superantigen-dependent-cellular-cytotoxicity, SDCC).Utilize this method just can such fused protein be navigated on the tumour cell and at tumour cell specifically and cause anticancer cell toxicant immunoreation on every side.
Through specific embodiment the present invention is further described below.
JEG-3 is used in experiment: as employed JEG-3 in the embodiment of the invention is murine sarcoma tumour Sarcoma (S180) tumour cell, human liver cancer cell Hep G2 and the human lung cancer cell A549 who is used to set up the mouse-borne tumor model, and these JEG-3s are available from ATCC.
EGF Receptor EGFR on the S180 cancer cells of existing report mouse and vegf receptor VEGFR can with EGF and VEGF interaction (PLoS One 6, e16642,2011 in people source; One Chinese patent application numbers 201010118438.1; " cytokine-superantigen fusion rotein is in the application of preparation solid tumor resisting medicine "); And the acceptor of TGF-α is identical with EGF; All be EGFR, so the S180 cancer cells can be used for the experiment that TGF, EGF or VEGF and SEE or SEE two mutants form fusion rotein.
Liver cancer cell is expressed acceptor GnRH-R (Endocrinology, 136,75-84,1995 of GnRH; Cancer Res, 60,3701-3705,2000), so Hep G2 cancer cells can be used for the experiment that GnRH and SEE or SEE two mutants form fusion rotein.
Lung carcinoma cell is expressed acceptor GRP-R (Oncogene, 20,1563-1569,2001 of GRP; Ann Oncol, 18,1457-1466,2007), so the A549 cancer cells can be used for the experiment that GRP and SEE or SEE two mutants form fusion rotein.
The two mutants of embodiment 1 design SEE
Because SEA and SEE have very big similarity (Infect Immun, 66,3337-3348,1998) on sequence, so the research of the space structure of SEA and other superantigen etc. can be used as reference (EMBO J, 14,3292-3301,1995 of SEE; J Biol Chem, 271,32212-32216,1996; J Mol Biol, 269,270-280,1997; Structure, 10,1619-1626,2002; Nature, 368,711-718,1994; Nature, 384,188-192,1996; J Mol Biol, 277,61-79,1998; Structure, 11,1151-1161,2003; EMBO J, 20,3306-3312,2001; J Mol Biol, 302,527-537,2000), in addition also with reference to relevant document (Nature, 346,471-473,1990; Infect Immun, 59,2126-2134,1991; J Exp Med, 175,415-424,1992; Proc Natl Acad Sci USA, 89,7727-7731,1992; J Exp Med, 177,175-184,1993; Infect Immun, 61,2059-2068,1993; J Biol Chem, 275,1665-1672,2000; Trends Microbiol, 8,369-375,2000; Immunity, 14,331-344,2001; Clin Exp Immunol, 133,299-306,2003; J Mol Biol, 333,893-905,2003; J Biol Chem, 278,50412-50421,2003; Scand J Immunol, 59,345-355,2004; Semin Immunol, 19,262-271,2007), through these information and SEE gene information (J Bacteriol, 170,2954-2960,1988; GenBank M21319) confirms the position of SEE point mutation, in the amino acid fragment of 20-27,34-49,74-84,187-190 and the 217-227 of the position of the point mutation that can consider in SEE, design as follows:
1. adopt among the SEA with TCR bonded amino acid segment because SEA has ability (Proc Natl Acad Sci USA, 91,8945-8949,1994 of very powerful inducing T cell; Proc Natl Acad Sci USA, 92,9791-9795,1995), designed 4 amino acid whose point mutation of the 20-27 position in the SEE sequence here: on 20, Arg → Gly; On 21, Asn → Thr; On 24, Ser → Gly; On 27, Arg → Lys.The point mutation of the two mutants of all SEE (SEE-1, SEE-2 and SEE-3) on this zone is all identical.
2. reduce and the combining of histocompatibility antigen MHC, acidity or basic aminoacids are become polar neutral amino acid (Ser or Thr) or nonpolar hydrophobic amino acid (Ala) or change its polar character (basic aminoacids becomes acidic amino acid or acidic amino acid becomes basic aminoacids) perhaps change amino acid whose side chain lengths.
2.1.SEE-1 the design of two mutants
On 34, Glu → Ser; On 39, Glu → Ser; On 40, Asn → Ser; On 41, Lys → Glu; On 42, Glu → Lys; On 44, Asp → Ala; On 49, Glu → Thr; On 74, Lys → Thr; On 75, Asp → Ala; On 78, Asn → Ser; On 79, Lys → Glu; On 81, Lys → Glu; On 83, Lys → Ser; On 84, Lys → Ser; On 217, Lys → Thr; On 220, Asn → Ser; On 222, Glu → Thr; On 223, Asn → Ser; On 225, His → Ser; On 227, Asp → Ser.Obtain the aminoacid sequence (SEQ ID NO.4) of SEE-1 at last.
2.2.SEE-2 the design of two mutants
On 34, Glu → Ser; On 35, Lys → Ser; On 39, Glu → Ser; On 40, Asn → Ser; On 41, Lys → Glu; On 42, Glu → Lys; On 44, Asp → Ser; On 45, Asp → Ala; On 46, Gln → Ser; On 49, Glu → Thr; On 74, Lys → Thr; On 75, Asp → Ala; On 78, Asn → Ser; On 79, Lys → Glu; On 81, Lys → Glu; On 83, Lys → Ser; On 84, Lys → Ser; On 188, Ser → Thr; On 190, Glu → Thr; On 217, Lys → Ser; On 219, Ile → Leu; On 220, Asn → Ser; On 222, Glu → Thr; On 223, Asn → Ser; On 224, Leu → Ile; On 225, His → Ser; On 227, Asp → Ser.Obtain the aminoacid sequence (SEQ ID NO.6) of SEE-2 at last.
2.3.SEE-3 the design of two mutants
On 34, Glu → Ala; On 35, Lys → Ser; On 36, Ala → Gly; On 39, Glu → Ser; On 40, Asn → Ala; On 41, Lys → Glu; On 42, Glu → Lys; On 44, Asp → Ser; On 45, Asp → Ala; On 46, Gln → Ser; On 49, Glu → Ser; On 62, Pro → Ser; On 74, Lys → Ser; On 75, Asp → Thr; On 77, Thr → Ser; On 78, Asn → Ser; On 79, Lys → Glu; On 81, Lys → Glu; On 83, Lys → Ser; On 84, Lys → Thr; On 188, Ser → Thr; On 190, Glu → Thr; On 217, Lys → Ser; On 218, Thr → Ser; On 219, Ile → Leu; On 220, Asn → Ser; On 221, Ser → Thr; On 222, Glu → Ser; On 223, Asn → Ser; On 224, Leu → Ile; On 225, His → Ser; On 227, Asp → Ser.Obtain the aminoacid sequence (SEQ ID NO.8) of SEE-3 at last.
The structure of embodiment 2 superantigens and two mutants expression vector thereof
The DNA nucleotide sequence of coding SEE derives from its gene information (J Bacteriol, 170,2954-2960,1988; The GenBank DB; M21319); And two mutants is the design according to embodiment 1; Entrust TAKARA company synthetic DNA fragment; It comprises sequence fragment and a connection peptides (shown in SEQ ID NO.50) of SEE gene or its two mutants and in several bases of whole pulsating front HindIII and back XhoI limiting enzyme point, synthetic good nucleic acid fragment is inserted the T carrier respectively and carries out dna sequencing and identify, and then with the double digestion method promptly with after HindIII and the XhoI processing; Insert fragment respectively on the pET22b plasmid, obtained to express carrier pET22b-SEE-1, pET22b-SEE-2 and the pET22b-SEE-3 of two mutants of carrier pET22b-SEE and the SEE of SEE gene.By the corresponding proteins sequence of these vector expressions, SEE is shown in the SEQ ID NO.2, and SEE-1 is shown in the SEQ ID NO.4, and SEE-2 is shown in the SEQ ID NO.6, and SEE-3 is shown in the SEQ ID NO.8.
The nucleotide sequence of coding SEE is shown in the SEQ ID NO.1, and the nucleotide sequence of coding SEE-1 is shown in the SEQ ID NO.3, and the nucleotide sequence of coding SEE-2 is shown in the SEQ ID NO.5, and the nucleotide sequence of coding SEE-3 is shown in the SEQ ID NO.7.
The nucleotide sequence of coding connection peptides is shown in the SEQ ID NO.49.
Embodiment 3TGF-α and SEE or SEE two mutants are formed the structure of Expression of Fusion Protein carrier
Information (NM_003236) according to the TGF-α gene in the people of GenBank DB source; Entrust the synthetic nucleic acid sequence fragments of TAKARA company to comprise TGF-α gene and increase the several bases that limit restriction enzyme site BamHI and EcoRI again, comprised the restriction restriction enzyme site of SalI and HindIII in pulsating back in TGF-α front.This synthetic good nucleic acid fragment is inserted the T carrier and carries out the dna sequencing evaluation; And then after promptly handling with the double digestion method with BamHI and HindIII; Insert this fragment respectively the carrier of pET22b-SEE, pET22b-SEE-1, pET22b-SEE-2 and pET22b-SEE-3 among the embodiment 2; So just produce expression vector pET22b-TGF-α-SEE, pET22b-TGF-α-SEE-1, pET22b-TGF-α-SEE-2 and pET22b-TGF-α-SEE-3, can express TGF-α-SEE (SEQ ID NO.10), TGF-α-SEE-1 (SEQ ID NO.12), TGF-α-SEE-2 (SEQ ID NO.14) and TGF-α-SEE-3 (SEQ ID NO.16) fusion rotein.
Embodiment 4EGF and SEE or SEE two mutants are formed the structure of Expression of Fusion Protein carrier
Information (NM_001963 and NM_001178130) according to the EGF gene in the people of GenBank DB source; Entrust the synthetic nucleic acid sequence fragments of TAKARA company to comprise the EGF gene and increase the several bases that limit restriction enzyme site BamHI and EcoRI again, comprised the restriction restriction enzyme site of SalI and HindIII in pulsating back in the EGF front.This synthetic good nucleic acid fragment is inserted the T carrier and carries out the dna sequencing evaluation; And then after promptly handling with the double digestion method with BamHI and HindIII; Insert this fragment respectively the carrier of pET22b-SEE, pET22b-SEE-1, pET22b-SEE-2 and pET22b-SEE-3 among the embodiment 2; So just produce expression vector pET22b-EGF-SEE, pET22b-EGF-SEE-1, pET22b-EGF-SEE-2 and pET22b-EGF-SEE-3, can express EGF-SEE (SEQ ID NO.18), EGF-SEE-1 (SEQ ID NO.20), EGF-SEE-2 (SEQ ID NO.22) and EGF-SEE-3 (SEQ ID NO.24) fusion rotein.
Embodiment 5VEGF and SEE or SEE two mutants are formed the structure of Expression of Fusion Protein carrier
Information (NM_003376) and reference papers (J.Biol.Chem. according to the VEGF gene in the people of GenBank DB source; 266; 11947-11954; 1991), entrust the synthetic nucleic acid sequence fragments of TAKARA company to comprise VEGF gene (121 amino acid) and increase the several bases that limit restriction enzyme site BamHI and EcoRI again, comprised the restriction restriction enzyme site of SalI and HindIII in pulsating back in the VEGF front.This synthetic good nucleic acid fragment is inserted the T carrier and carries out the dna sequencing evaluation; And then after promptly handling with the double digestion method with BamHI and HindIII; Insert this fragment respectively the carrier of pET22b-SEE, pET22b-SEE-1, pET22b-SEE-2 and pET22b-SEE-3 among the embodiment 2; So just produced expression vector pET22b-VEGF-SEE, pET22b-VEGF-SEE-1, pET22b-VEGF-SEE-2 and pET22b-VEGF-SEE-3, but VEGF expression-SEE (SEQ ID NO.26), VEGF-SEE-1 (SEQ ID NO.28), VEGF-SEE-2 (SEQ ID NO.30) and VEGF-SEE-3 (SEQ ID NO.32) fusion rotein.
Embodiment 6GnRH and SEE or SEE two mutants are formed the structure of Expression of Fusion Protein carrier
Information (NM_021081 and NM_000825 etc.) according to the GnRH gene in the people of GenBank DB source; Entrust the synthetic nucleic acid sequence fragments of TAKARA company to comprise the GnRH gene and increase the several bases that limit restriction enzyme site BamHI and EcoRI again, comprised the restriction restriction enzyme site of SalI and HindIII in pulsating back in the GnRH front.This synthetic good nucleic acid fragment is inserted the T carrier and carries out the dna sequencing evaluation; And then after promptly handling with the double digestion method with BamHI and HindIII; Insert this fragment respectively the carrier of pET22b-SEE, pET22b-SEE-1, pET22b-SEE-2 and pET22b-SEE-3 among the embodiment 2; So just produce expression vector pET22b-GnRH-SEE, pET22b-GnRH-SEE-1, pET22b-GnRH-SEE-2 and pET22b-GnRH-SEE-3, can express GnRH-SEE (SEQ ID NO.34), GnRH-SEE-1 (SEQ ID NO.36), GnRH-SEE-2 (SEQ ID NO.38) and GnRH-SEE-3 (SEQ ID NO.40) fusion rotein.
Embodiment 7GRP and SEE or SEE two mutants are formed the structure of Expression of Fusion Protein carrier
Information (NM_002091, NM_001012512 and NM_001012513 etc.) according to the GRP gene in the people of GenBank DB source; Entrust the synthetic nucleic acid sequence fragments of TAKARA company to comprise the GnRH gene and increase the several bases that limit restriction enzyme site BamHI and EcoRI again, comprised the restriction restriction enzyme site of SalI and HindIII in pulsating back in the GnRH front.This synthetic good nucleic acid fragment is inserted the T carrier and carries out the dna sequencing evaluation; And then after promptly handling with the double digestion method with BamHI and HindIII; Insert this fragment respectively the carrier of pET22b-SEE, pET22b-SEE-1, pET22b-SEE-2 and pET22b-SEE-3 among the embodiment 2; So just produce expression vector pET22b-GRP-SEE, pET22b-GRP-SEE-1, pET22b-GRP-SEE-2 and pET22b-GRP-SEE-3, can express GRP-SEE (SEQ ID NO.42), GRP-SEE-1 (SEQ ID NO.44), GRP-SEE-2 (SEQ ID NO.46) and GRP-SEE-3 (SEQ ID NO.48) fusion rotein.
Change various expression plasmid pET22b-TGF-α-SEE, pET22b-TGF-α-SEE-1, pET22b-TGF-α-SEE-2, pET22b-TGF-α-SEE-3, pET22b-EGF-SEE, pET22b-EGF-SEE-1, pET22b-EGF-SEE-2, pET22b-EGF-SEE-3, pET22b-VEGF-SEE, pET22b-VEGF-SEE-1, pET22b-VEGF-SEE-2, pET22b-VEGF-SEE-3, pET22b-GnRH-SEE, pET22b-GnRH-SEE-1, pET22b-GnRH-SEE-2, pET22b-GnRH-SEE-3, pET22b-GRP-SEE, pET22b-GRP-SEE-1, pET22b-GRP-SEE-2 and pET22b-GRP-SEE-3 over to e. coli bl21 (DE3) with electroporation respectively, utilize microbiotic Amp (Ampicillin) screening positive bacteria.The process of next various proteic expression, sex change and renaturation and purifying is roughly the same, operates as follows:
The e. coli bl21 (DE3) that contains expression plasmid carries out extensive 37 ℃ of cultivations earlier, add then IPTG (Isopropylthio-β-D-galactoside) makes it concentration and reaches 1mM and spend the night 30 ℃ and cultivate, thus abduction delivering albumen.The 2nd day centrifugation medium with collect thalline, use the supersonic method breaking cell wall, centrifugal collection inclusion body precipitates, the albumen here is to exist with the inclusion body form.Inclusion body albumen is with the urea-denatured dissolving of 6M, carries out the multistage dialysis then, and dialysis solution is for example 3M, 2M and 1M of the urea that progressively dilutes; Next be 0.5M urea; 0.4M the L-l-arginine, 375 μ M Sleep-promoting factor B GSSG, 1.875mM reduced glutathion GSH; Carry out centrifugally after the dialysis, the gained supernatant is exactly proteic renaturation solution.Carry out purifying with HisBind Purification Kit test kit (Novagen company) for albumen; With Binding Buffer flushing gel column, also in protein solution, add Binding Buffer simultaneously, earlier with the protein sample upper prop; With Wash Buffer rinsing; Using Elute Buffer wash-out then, identify with protein electrophorese, is that the albumen of a band is used for later experiment with purity.Obtain various high purity fusion rotein TGF-α-SEE, TGF-α-SEE-1, TGF-α-SEE-2, TGF-α-SEE-3, EGF-SEE, EGF-SEE-1, EGF-SEE-2, EGF-SEE-3, VEGF-SEE, VEGF-SEE-1, VEGF-SEE-2, VEGF-SEE-3, GnRH-SEE, GnRH-SEE-1, GnRH-SEE-2, GnRH-SEE-3, GRP-SEE, GRP-SEE-1, GRP-SEE-2 and GRP-SEE-3 like this.
At first select 450 of male ICR mouses, in 4-5 week, 18-22g, murine sarcoma cell S180 buy from ATCC, carry out vitro culture earlier, are expelled to the ICR mouse peritoneal again, carry out large scale culturing in the body, and be last, takes out Intraabdominal S180 cell, with 2x10
6Murine sarcoma cell S180 is inoculated in the oxter, right side of ICR mouse.
Embodiment 10TGF-α-SEE, TGF-α-SEE-1, TGF-α-SEE-2 and TGF-α-SEE-3 fusion rotein suppresses the mouse tumor experiment
Get 150 tumor-bearing mices among the embodiment 9; Be divided into 5 groups; Every group 30, injected TGF-α-SEE, TGF-α-SEE-1, TGF-α-SEE-2 and TGF-α-SEE-3 fusion rotein respectively in the 2nd, 4,6,8 day behind the inoculated tumour cell, dosage is 100pmol; A control group injecting normal saline killed mouse on the 9th day.The result shows that TGF-α-SEE, TGF-α-SEE-1, TGF-α-SEE-2 and TGF-α-SEE-3 have restraining effect to growth of tumor; Wherein, TGF-α-SEE-2 and TGF-α-SEE-3 have shown better effect; Tumour occurs organizing late 1-2 days than other, and very little tumour (Fig. 1) appears in TGF-α-SEE-3 medication group the 7th talent.
Embodiment 11EGF-SEE, EGF-SEE-1, EGF-SEE-2 and EGF-SEE-3 fusion rotein suppress the mouse tumor experiment
Get 150 tumor-bearing mices among the embodiment 9; Be divided into 5 groups; Every group 30, injected EGF-SEE, EGF-SEE-1, EGF-SEE-2 and EGF-SEE-3 fusion rotein respectively in the 2nd, 4,6,8 day behind the inoculated tumour cell, dosage is 100pmol; A control group injecting normal saline killed mouse on the 9th day.The result shows that EGF-SEE, EGF-SEE-1, EGF-SEE-2 and EGF-SEE-3 have restraining effect to growth of tumor; Wherein, EGF-SEE-2 and EGF-SEE-3 have shown better effect; Tumour occurs organizing late 1-2 days than other, and very little tumour (Fig. 2) appears in EGF-SEE-3 medication group the 7th talent.
Embodiment 12VEGF-SEE, VEGF-SEE-1, VEGF-SEE-2 and VEGF-SEE-3 fusion rotein suppress the mouse tumor experiment
Get 150 tumor-bearing mices among the embodiment 9; Be divided into 5 groups; Every group 30, the 2nd, 4,6,8 day difference injection of VEGF-SEE, VEGF-SEE-1, VEGF-SEE-2 and VEGF-SEE-3 fusion rotein behind the inoculated tumour cell, dosage is 100pmol; A control group injecting normal saline killed mouse on the 9th day.The result shows that VEGF-SEE, VEGF-SEE-1, VEGF-SEE-2 and VEGF-SEE-3 have restraining effect to growth of tumor; Wherein, VEGF-SEE-2 and VEGF-SEE-3 have shown better effect; Tumour occurs organizing late 1-2 days than other, and very little tumour (Fig. 3) appears in VEGF-SEE-3 medication group the 7th talent.
The lymphocytic detection of T in embodiment 13 tumor tissues
The S180 tumor tissues of the various fusion rotein administration of process among embodiment 10-12 mouse and the mouse S180 tumor tissues of control group saline water are cut into small pieces, process paraffin section, carry out immunohistochemical assay then with paraffin embedding.In order to detect the T cell in the tumor tissues, use the anti-cd 3 antibodies of Santa Cruz Biotechnolog company, the anti-and avidin-biotin-perxidase complex (Zymed company) with two uses Diaminobenzidine (DAB) colour developing at last then.(among the figure: 4-1 is TGF-α-SEE-3 administration group to Fig. 4; 4-2 is an EGF-SEE-3 administration group; 4-3 is a VEGF-SEE-3 administration group) experimental result of the fusion rotein just formed by SEE-3, utilize the detected T cell of immunohistochemical methods method, brown point is the T cell.
Through testing: also all found the existence of T cell in the mouse tumor tissue of the administration group of TGF-α-SEE, TGF-α-SEE-1, TGF-α-SEE-2, EGF-SEE, EGF-SEE-1, EGF-SEE-2, VEGF-SEE, VEGF-SEE-1 and VEGF-SEE-2 fusion rotein.
The detection of embodiment 14 tumor tissues internal interference element-γ (IFN-γ)
Adopt with embodiment 13 similar immunohistochemical methods and detect the interior cytokine IFN-γ by T emiocytosis of tumor tissues among the embodiment 10-12, antibody is the anti-IFN-gamma antibodies of Santa Cruz Biotechnolog company.(among the figure: 5-1 is TGF-α-SEE-3 administration group to Fig. 5; 5-2 is an EGF-SEE-3 administration group; 5-3 is a VEGF-SEE-3 administration group) utilize the detected interferon-of immunohistochemical methods (IFN-γ) by T emiocytosis, brown part is IFN-γ.
Through testing: also all found existence in the mouse tumor tissue of the administration group of TGF-α-SEE, TGF-α-SEE-1, TGF-α-SEE-2, EGF-SEE, EGF-SEE-1, EGF-SEE-2, VEGF-SEE, VEGF-SEE-1 and VEGF-SEE-2 fusion rotein by the IFN-γ of induced t cell.
Embodiment 15 calf serums and fusion rotein hatch experiment
The calf serum dilution that the GnRH-SEE of employed high density, GnRH-SEE-1, GnRH-SEE-2, GnRH-SEE-3, GRP-SEE, GRP-SEE-1, GRP-SEE-2 and GRP-SEE-3 fusion rotein are all cultivated with cancer cells in the cancer cells culture experiment; Under 37 ℃, hatched 5 hours then, employed these fusion roteins all pass through the processing of hatching of calf serum in the experiment of all cancer cells later on.The experiment of hatching here is that whether the biological activity of fusion rotein changes under the situation for the existence of the basic antibody (IgM and IgG etc.) of checking opposing proteasome degradation and the anti-superantigen in thermally-stabilised etc. and the serum in calf serum.
The inducer T lymphocyte of embodiment 16GnRH-SEE, GnRH-SEE-1, GnRH-SEE-2, GnRH-SEE-3, GRP-SEE, GRP-SEE-1, GRP-SEE-2 and GRP-SEE-3 fusion rotein is active
The human peripheral blood cell obtains T lymphocyte (J Clin Invest, 91 available from the Tianjin Blood Center with Ficoll density centrifugation and nylon hair column method; 1490-1498; 1993), these T cells are used the DMEM culture medium culturing on 6 orifice plates, and add 10% calf serum.There is 5x10 in each hole
5Individual T cell; The GnRH-SEE, GnRH-SEE-1, GnRH-SEE-2, GnRH-SEE-3, GRP-SEE, GRP-SEE-1, GRP-SEE-2 and the GRP-SEE-3 fusion rotein that add the 5pmol amount then; These albumen all pass through hatching of calf serum, use the IFN-γ test kit (R&D Systems company) of enzyme-linked immunosorbent assay (ELISA) to detect the content of the IFN-γ in the substratum then.
Table 1 is for analyzing GnRH-SEE, GnRH-SEE-1, GnRH-SEE-2 and GnRH-SEE-3 fusion rotein and stimulate the ability of T cell, detection be cytokine IFN-γ.
That table 1 detects is cytokine IFN-γ (pg/ml)
The result shows the vigor that GnRH-SEE, GnRH-SEE-1, GnRH-SEE-2 and GnRH-SEE-3 fusion rotein all have stimulates the T cell, and wherein, GnRH-SEE-2 and GnRH-SEE-3 fusion rotein have shown the vigor of stronger stimulation T cell.
Table 2 is for analyzing GRP-SEE, GRP-SEE-1, GRP-SEE-2 and GRP-SEE-3 fusion rotein and stimulate the ability of T cell, detection be cytokine IFN-γ.
That table 2 detects is cytokine IFN-γ (pg/ml)
The result shows the vigor that GRP-SEE, GRP-SEE-1, GRP-SEE-2 and GRP-SEE-3 fusion rotein all have stimulates the T cell, and wherein, GRP-SEE-2 and GRP-SEE-3 fusion rotein have shown the vigor of stronger stimulation T cell.
Embodiment 17GnRH-SEE, GnRH-SEE-1, GnRH-SEE-2, GnRH-SEE-3, GRP-SEE, GRP-SEE-1, GRP-SEE-2 and GRP-SEE-3 fusion rotein kill and wound cancer cells
With the liver cancer cell Hep G2 and the lung cell A549 in DMEM culture medium culturing human cancer cell source, the cancer cells number is 5x10 on 6 orifice plates
5Individual cancer cells/hole adds the T cell then, is that 10 times of cancer cells are 5x10
6Individual T cells/well; GnRH-SEE, GnRH-SEE-1, GnRH-SEE-2, GnRH-SEE-3, GRP-SEE, GRP-SEE-1, GRP-SEE-2 and the GRP-SEE-3 fusion rotein that calf serum is hatched that pass through that adds various dosage more respectively; Wherein, GnRH superantigen fusion rotein joins liver cancer cell Hep G2 culture hole, and GRP superantigen fusion rotein joins the lung cell A549 culture hole.
CDCC or cancer cells fragmentation effect adopt MTT (Methabenzthiazuron) method to measure (Immunology, 82,117-125,1994), and the cell growth-inhibiting is with 100-[(A
Test-A
b)/(A
c-A
b)] calculating of x100 formula, A
TestRefer to the growth of cancer cells under the adding of T cell, A
bRefer to and have only substratum, A in the hole
cRefer to growth of cancer cells.The number of times of every kind of cancer cells killing experiments is all more than 20 later on.
Fig. 6 is an experimental result, shows that GnRH-SEE, GnRH-SEE-1, GnRH-SEE-2, GnRH-SEE-3 have the ability of killing hepatoma cell Hep G2, and wherein GnRH-SEE-2 and GnRH-SEE-3 just have higher cancer cells lethal effect under very low dosage.
Fig. 7 is an experimental result, shows that GRP-SEE, GRP-SEE-1, GRP-SEE-2 and GRP-SEE-3 have the ability of killing and wounding lung cell A549, and wherein GRP-SEE-2 and GRP-SEE-3 just have higher cancer cells lethal effect under very low dosage.
(among the figure: 8-1 is the GnRH-SEE-3 group to Fig. 8; 8-2 is a GRP-SEE-3 group) cancer cells of being attacked by the T cell that shows, maxicell is a cancer cells, minicell is the T cell.
In experiment: GnRH-SEE, GnRH-SEE-1, GnRH-SEE-2, GRP-SEE, GRP-SEE-1 and GRP-SEE-2 group, also observed the phenomenon of the cancer cells of T cell attack.
The present invention has selected a kind of superantigen SEE and two mutants thereof, makes the SEE two mutants than SEE more powerful induced t cell ability arranged, and more can resist the antibody neutralizing effect in the blood.TGF-α-the SEE, EGF-SEE, VEGF-SEE, GnRH-SEE and the GRP-SEE that form by SEE; TGF-α-SEE-2, EGF-SEE-2, VEGF-SEE-2, GnRH-SEE-2 and GRP-SEE-2 and the TGF-α-SEE-3 that is made up of SEE-3, EGF-SEE-3, VEGF-SEE-3, GnRH-SEE-3 and the GRP-SEE-3 fusion rotein be made up of SEE-2 all have antitumous effect; Wherein, TGF-α-SEE-2, EGF-SEE-2, VEGF-SEE-2, GnRH-SEE-2, GRP-SEE-2TGF-α-SEE-3, EGF-SEE-3, VEGF-SEE-3, GnRH-SEE-3 and GRP-SEE-3 fusion rotein have shown stronger cancer cells and the anti-tumor bioactivity of killing and wounding.
Two mutants SEE-1, SEE-2 and the SEE-3 of the superantigen SEE here is selected from SEE and introduced extensive a plurality of point mutation; Because SEA and SEE are at the homogeny that has on the aminoacid sequence more than 80%, so can also can obtain the two mutants of SEE from SEA through point mutation.Through the molecular biology working method of range gene point mutation, on existing SEE two mutants, introduce point mutation and obtain the higher superantigen of biological activity in addition.
Determined point mutation position from embodiment 1, the amino acid that on these positions, can introduce other similar physico-chemical property also can obtain the biological activity identical or higher with the SEE two mutants.
From bigger scope; Other superantigen is the SEB, SEC, SED, SEF, SEG, SEH, SEI, SEJ etc. of Staphylococcus aureus enterotoxin family for example; The SPE-A of streptococcus toxin, SPE-B, SPE-C; Shock syndrome toxin (Shock syndrome toxin), the superantigen in viral protein source can be strengthened the T cytositimulation ability of superantigen, the stability of superantigen and the neutralizing effect of resisting the superantigen of antibody in the blood through the multipoint mutation means.
Can select and the interactional peptide molecule of cancer cells surface receptor as another part of SEE and mutant fusion protein thereof; Such polypeptide has Prostatropin (Basic fibroblast growth factor; BFGF) and FGF family, interleukin-family (Interleukin) for example interleukin II, interleukin 3, interleukin 4, interleukin-6, interleukin 8, interleukin 11, IL-13, rHuGM-CSF (Granulocyte-macrophage colony-stimulating factor; GM-CSF), heparin combines EGF like growth factor (Heparin-binding EGF-like growth factor; HB-EGF), rhIGF-1 (Insulin-like growth factor; IGF), pHGF (Hepatocyte growth factor; HGF), Thr6 PDGF BB (Platelet-derived growth factor; PDGF), NGFF (Nerve growth factor; NGF), PlGF (Placental growth factor; PGF), STEMCELLFACTOR (Stem cell factor; SCF), Heregulin, erbB part, various chemokine (Chemokine) and family, Ephrin family, angiogenin (Angiopoietin), TSF (Thrombopoietin) and the blood plasma VII factor (Factor VII), urokinase type plasminogen activator (Urokinase-type plasminogen activator), growth hormone releasing hormone (Growth hormone releasing hormone), melanotropin α-MSH, prolactin antagonist (Prolactin), prolactin releasing hormone (PRH) (Prolactin releasing hormone), tethelin (Growth hormone), follicle stimulating hormone (Follicle stimulating hormone), placental lactogen hormone (Placental lactogen), chorionic-gonadotropin hormone (Chorionic gonadotropin) and corticotropin releasing hormone (Corticotropin releasing hormone), Somatostatin (Somatostatin), asialoglycoprotein gp (Asialoglycoprotein), low-density lipoprotein (Low density lipoprotein) and Transferrins,iron complexes (Transferrin) etc., and these proteic aminoacid sequences have the nature of the homogeny more than 70% and artificial varient etc.Many tumor tissues are these material acceptors of overexpression all; Thereby peptide molecule parts such as chemokine, enzyme, hormone and other albumen just can be connected to form fused protein with costimulatory molecules as cytokine, costimulatory molecules is navigated in the tumor tissues.
Top fused protein can also be connected polypeptide of cytokine, hormone or the non-hormone of the non-antibody acellular factor etc. respectively through means such as chemical crosslink reactions with the protein fragments of superantigen, for example covalent linkage connects and makes up.Can carry out a part of polypeptide fragment of chemically modified, damaged fused protein and other polypeptide chain is connected on the first-class a series of transformation of these protein for fused protein.Fused protein behind the purifying can improve the space structure that it comprises disulfide linkage through a series of proteinic sex change and renaturation process, improves its biological activity.
From bigger scope; The acceptor of over-expresses is actually interactional relation between a kind of part and the acceptor on the polypeptide of cytokine, hormone or the non-hormone of the non-antibody acellular factor that is adopted in the experiment here and its corresponding cancer cells surface; Utilize the avidity of this part and acceptor, superantigen is navigated to tumor tissues.Except cytokine, hormone or polypeptide, other is every to be the specific localization that part also can be used for cancer cells with corresponding protein of the acceptor of cancer cells over-expresses or peptide molecule.The corresponding part of acceptor on top said and cancer cells, screen from phage display methods such as (Phage display) with cancer cells on acceptor avidity is arranged and have antagonistic action artificial screening protein or polypeptide and with other method screen can be directly and the protein of cancer cells surface interaction or peptide molecule can form fused protein with costimulatory molecules.
As its formulation of medicine can be emulsifying agent, liposome, dispersion agent, stablizer etc. process together various injections, oral, apply ointment or plaster and the form of medication of medicine such as surgical procedure.Except fused protein itself can be used as the medicine, the nucleotide fragments of encoding fusion protein matter or carrier can also be used as the gene therapy form.
In the specific embodiment of the present invention; TGF-α-SEE, EGF-SEE and VEGF-SEE that said cytokine-superantigen fusion rotein is made up of SEE; TGF-α-the SEE-1, EGF-SEE-1 and the VEGF-SEE-1 that form by the two mutants SEE-1 of SEE; TGF-α-the SEE-2, EGF-SEE-2 and the VEGF-SEE-2 that form by the two mutants SEE-2 of SEE, and the TGF-α-SEE-3, EGF-SEE-3 and the VEGF-SEE-3 that form by the two mutants SEE-3 of SEE; The GnRH-SEE that said hormone-the superantigen fusion rotein is made up of SEE, the GnRH-SEE-1 that forms by the two mutants SEE-1 of SEE, the GnRH-SEE-2 that forms by the two mutants SEE-2 of SEE, and the GnRH-SEE-3 that forms by the two mutants SEE-3 of SEE; The GRP-SEE that polypeptide-the superantigen fusion rotein is made up of SEE of the non-hormone of the said non-antibody acellular factor; The GRP-SEE-1 that forms by the two mutants SEE-1 of SEE; The GRP-SEE-2 that forms by the two mutants SEE-2 of SEE, and the GRP-SEE-3 that forms by the two mutants SEE-3 of SEE.These fusion roteins can induce and stimulate the T lymphocyte to come anti-respectively sarcoma S180, Hep G2 liver cancer and A549 lung cancer; But; As long as the cancer cells (cell in various internal organs, the blood, bone, brain, intestines and skin etc.) of other kind is gone up the acceptor of expressing TGF-α, EGF, VEGF, GnRH and GRP; Can adopt the fusion rotein here to come killing tumor cells, thereby be applied to the treatment of various cancers or malignant tumour.
The description of above embodiment and preferred implementation belongs to the schematic illustration of the present invention that claim is limited, rather than restriction the present invention.What need particularly point out is, only otherwise break away from aim of the present invention, all conspicuous changes and the similar invention with equivalent substitution all are included within protection scope of the present invention.
Claims (10)
1. cancer-targeted super antigen fusion rotein is characterized in that this fusion rotein contains:
A) promote growth of cancer cells and with the part of cancer cells over-expresses acceptor interaction, said part is the polypeptide of cytokine, hormone or the non-hormone of the non-antibody acellular factor;
B) can cause superantigen staphylococcus aureus enterotoxin E and the two mutants thereof that antitumor immune reacts, said staphylococcus aureus enterotoxin E is represented with abbreviation SEE; The two mutants of said staphylococcus aureus enterotoxin E is represented said X=1-3 with abbreviation SEE-X.
2. a kind of cancer-targeted super antigen fusion rotein according to claim 1 is characterized in that said cytokine is selected from transforminggrowthfactor-, the Urogastron of being abbreviated as EGF of being abbreviated as TGF-α, the vascular endothelial growth factor of being abbreviated as VEGF; Said hormone is selected from the gonadotropin releasing hormone of being abbreviated as GnRH; The polypeptide of the non-hormone of the said non-antibody acellular factor is selected from the gastrin releasing peptide of being abbreviated as GRP.
3. a kind of cancer-targeted super antigen fusion rotein according to claim 1 is characterized in that said SEE is the aminoacid sequence shown in the SEQ ID No.2; Said SEE-1 is the aminoacid sequence shown in the SEQ ID No.4; Said SEE-2 is the aminoacid sequence shown in the SEQ ID No.6; Said SEE-3 is the aminoacid sequence shown in the SEQ ID No.8.
4. a kind of cancer-targeted super antigen fusion rotein according to claim 3 is characterized in that said SEE-1 is that one or more amino acid on 20,21,24,27,34,39,40,1,42,44,49,74,75,78,79,81,83,84,217,220,222,223,225,227 on the SEE are replaced.
5. a kind of cancer-targeted super antigen fusion rotein according to claim 3 is characterized in that said SEE-2 is that one or more amino acid on 20,21,24,27,34,35,39,40,41,42,44,45,46,49,74,75,78,79,81,83,84,188,190,217,219,220,222,223,224,225,227 on the SEE are replaced.
6. a kind of cancer-targeted super antigen fusion rotein according to claim 3 is characterized in that said SEE-3 is that one or more amino acid on 20,21,24,27,34,35,36,39,40,41,42,44,45,46,49,62,74,75,77,78,79,81,83,84,188,190,217,218,219,220,221,222,223,224,225,227 on the SEE are replaced.
7. a kind of cancer-targeted super antigen fusion rotein according to claim 1 is characterized in that said this fusion rotein is:
By the TGF-α-SEE shown in the SEQ ID No.10;
By the EGF-SEE shown in the SEQ ID No.18;
By the VEGF-SEE shown in the SEQ ID No.26;
By the GnRH-SEE shown in the SEQ ID No.34;
By the GRP-SEE shown in the SEQ ID No.42;
By the TGF-α-SEE-1 shown in the SEQ ID No.12;
By the EGF-SEE-1 shown in the SEQ ID No.20;
By the VEGF-SEE-1 shown in the SEQ ID No.28;
By the GnRH-SEE-1 shown in the SEQ ID No.36;
By the GRP-SEE-1 shown in the SEQ ID No.44;
By the TGF-α-SEE-2 shown in the SEQ ID No.14;
By the EGF-SEE-2 shown in the SEQ ID No.22;
By the VEGF-SEE-2 shown in the SEQ ID No.30;
By the GnRH-SEE-2 shown in the SEQ ID No.38;
By the GRP-SEE-2 shown in the SEQ ID No.46;
By the TGF-α-SEE-3 shown in the SEQ ID No.16;
By the EGF-SEE-3 shown in the SEQ ID No.24;
By the VEGF-SEE-3 shown in the SEQ ID No.32;
By the GnRH-SEE-3 shown in the SEQ ID No.40;
Or by the GRP-SEE-3 shown in the SEQ ID No.48.
8. recombinant vectors is characterized in that containing the nucleotide sequence of the said fusion rotein of coding claim 7, and said nucleotides sequence is classified the nucleotide sequence SEQ ID No.9 of coding SEQ ID No.10 as;
The nucleotide sequence SEQ ID No.11 of coding SEQ ID No.12;
The nucleotide sequence SEQ ID No.13 of coding SEQ ID No.14;
The nucleotide sequence SEQ ID No.15 of coding SEQ ID No.16;
The nucleotide sequence SEQ ID No.17 of coding SEQ ID No.18;
The nucleotide sequence SEQ ID No.19 of coding SEQ ID No.20;
The nucleotide sequence SEQ ID No.21 of coding SEQ ID No.22;
The nucleotide sequence SEQ ID No.23 of coding SEQ ID No.24;
The nucleotide sequence SEQ ID No.25 of coding SEQ ID No.26;
The nucleotide sequence SEQ ID No.27 of coding SEQ ID No.28;
The nucleotide sequence SEQ ID No.29 of coding SEQ ID No.30;
The nucleotide sequence SEQ ID No.31 of coding SEQ ID No.32;
The nucleotide sequence SEQ ID No.33 of coding SEQ ID No.34;
The nucleotide sequence SEQ ID No.35 of coding SEQ ID No.36;
The nucleotide sequence SEQ ID No.37 of coding SEQ ID No.38;
The nucleotide sequence SEQ ID No.39 of coding SEQ ID No.40;
The nucleotide sequence SEQ ID No.41 of coding SEQ ID No.42;
The nucleotide sequence SEQ ID No.43 of coding SEQ ID No.44;
The nucleotide sequence SEQ ID No.45 of coding SEQ ID No.46;
Or shown in the nucleotide sequence SEQ ID No.47 of coding SEQ ID No.48.
9. the preparation method of the said a kind of cancer-targeted super antigen fusion rotein of claim 1 is characterized in that cultivating the host cell that contains the said recombinant vectors of claim 8, collects and expresses the described fusion rotein of claim 1.
10. the described fusion rotein of claim 1 is in the application of the medicine of preparation treatment cancer and anti entity tumour.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110378799.4A CN102516392B (en) | 2011-11-25 | 2011-11-25 | Cancer-targeted super antigen fusion protein, and preparation method and application thereof |
PCT/CN2012/082495 WO2013075553A1 (en) | 2011-11-25 | 2012-09-29 | Superantigen fusion protein targeting cancer and preparation method and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110378799.4A CN102516392B (en) | 2011-11-25 | 2011-11-25 | Cancer-targeted super antigen fusion protein, and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102516392A true CN102516392A (en) | 2012-06-27 |
CN102516392B CN102516392B (en) | 2014-05-28 |
Family
ID=46287503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110378799.4A Active CN102516392B (en) | 2011-11-25 | 2011-11-25 | Cancer-targeted super antigen fusion protein, and preparation method and application thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN102516392B (en) |
WO (1) | WO2013075553A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013075553A1 (en) * | 2011-11-25 | 2013-05-30 | Sun Jialin | Superantigen fusion protein targeting cancer and preparation method and use thereof |
CN103965302A (en) * | 2013-01-29 | 2014-08-06 | 中国人民解放军军事医学科学院微生物流行病研究所 | Recombinant superantigen SEB mutant, preparation method and applications thereof |
CN106085932A (en) * | 2016-05-19 | 2016-11-09 | 中国药科大学 | A kind of structure of the genetic engineering bacterium of VEGF Yu GnRH fusion protein of recombinating |
CN108611309A (en) * | 2018-04-28 | 2018-10-02 | 中国药科大学 | A kind of structure of expression recombination GnRH and the genetic engineering bacterium of GRP fusion proteins |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1152877A (en) * | 1994-07-11 | 1997-06-25 | 法马西亚及厄普约翰公司 | Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate |
CN1629194A (en) * | 2003-12-21 | 2005-06-22 | 孙嘉琳 | Super antigen fusion protein for cancer therapy and its producing method |
CN101998965A (en) * | 2007-11-01 | 2011-03-30 | 珀西德治疗有限责任公司 | Immunosuppressive polypeptides and nucleic acid |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0102327D0 (en) * | 2001-06-28 | 2001-06-28 | Active Biotech Ab | A novel engineered superantigen for human therapy |
CN1880336A (en) * | 2005-06-15 | 2006-12-20 | 孙嘉琳 | Cancer-targeted super antigen fusion protein and its production method |
CN101829322A (en) * | 2010-03-05 | 2010-09-15 | 孙嘉琳 | Application of superantigen fusion protein cell factor in preparation of anti-solid tumor medicament |
CN102114239A (en) * | 2010-12-14 | 2011-07-06 | 孙嘉琳 | Application of cell factor-super-antigen fusion protein in preparation of anti-cancer drugs |
CN102516392B (en) * | 2011-11-25 | 2014-05-28 | 孙嘉琳 | Cancer-targeted super antigen fusion protein, and preparation method and application thereof |
-
2011
- 2011-11-25 CN CN201110378799.4A patent/CN102516392B/en active Active
-
2012
- 2012-09-29 WO PCT/CN2012/082495 patent/WO2013075553A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1152877A (en) * | 1994-07-11 | 1997-06-25 | 法马西亚及厄普约翰公司 | Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate |
CN1629194A (en) * | 2003-12-21 | 2005-06-22 | 孙嘉琳 | Super antigen fusion protein for cancer therapy and its producing method |
CN101998965A (en) * | 2007-11-01 | 2011-03-30 | 珀西德治疗有限责任公司 | Immunosuppressive polypeptides and nucleic acid |
Non-Patent Citations (3)
Title |
---|
SOLTIS,M.T. ETAL: "S.aureus entertoxin type E (entE) gene, complete cds", 《S.AUREUS ENTERTOXIN TYPE E (ENTE) GENE, COMPLETE CDS》 * |
张伟: "金黄色葡萄球菌肠毒素E的克隆表达和生物活性研究以及基因组DNA固定化研究", 《中国优秀硕士学位论文全文数据库医药卫生科技辑》 * |
熊茂林: "GPI锚的结构、功能及GPI锚定B7分子在肿瘤免疫治疗中的应用", 《国外医学免疫学分册》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013075553A1 (en) * | 2011-11-25 | 2013-05-30 | Sun Jialin | Superantigen fusion protein targeting cancer and preparation method and use thereof |
CN103965302A (en) * | 2013-01-29 | 2014-08-06 | 中国人民解放军军事医学科学院微生物流行病研究所 | Recombinant superantigen SEB mutant, preparation method and applications thereof |
CN103965302B (en) * | 2013-01-29 | 2019-05-28 | 军事科学院军事医学研究院微生物流行病研究所 | A kind of recombination super antigen SEB mutant, preparation method and application |
CN106085932A (en) * | 2016-05-19 | 2016-11-09 | 中国药科大学 | A kind of structure of the genetic engineering bacterium of VEGF Yu GnRH fusion protein of recombinating |
CN108611309A (en) * | 2018-04-28 | 2018-10-02 | 中国药科大学 | A kind of structure of expression recombination GnRH and the genetic engineering bacterium of GRP fusion proteins |
Also Published As
Publication number | Publication date |
---|---|
CN102516392B (en) | 2014-05-28 |
WO2013075553A1 (en) | 2013-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106282216B (en) | A kind of preparation method of recombinant long-acting chicken interferon α | |
CN108840923B (en) | Polypeptide targeting PD-L1 and application thereof | |
CN101955545B (en) | Multi-target recombination gene and application of protein thereof in preventing and treating infection of helicobacter pylori | |
CN109336976A (en) | The nano antibody of anti-human EGFR and its application | |
CN102516392B (en) | Cancer-targeted super antigen fusion protein, and preparation method and application thereof | |
CN106565836A (en) | High-affinity soluble PDL-1 molecule | |
CN108484776B (en) | A kind of fusion protein, preparation method and applications | |
WO2019154103A1 (en) | Novel polypeptide for tumor targeting and application thereof | |
CN104193828B (en) | The recombination fusion protein of HER2 and VEGFR signal paths is blocked simultaneously | |
CN103421832B (en) | Comprise yolk antibody and the preparation and application of florfenicol Drug Resistance Gene Associated Proteins | |
CN112111013A (en) | Universal chimeric antigen receptor T cell targeting claudin18.2, construction method and application thereof | |
CN101245098B (en) | Antimicrobial antiphlogistic antagonism polypeptide simulating MD2 | |
CN102391377B (en) | Fusion protein capable of inducing and activating cancer targeting T-cells as well as preparation method and application of the fusion protein | |
CN108314718A (en) | A kind of house fly antibiotic peptide MAF-1A peptides aggressiveness, its encoding gene and its expression and application | |
CN103360497A (en) | Novel antitumor fusion protein vaccine, and preparation method and application thereof | |
CN101015689A (en) | Tumour polypeptide vaccine based on angiotensin II | |
CN102559605A (en) | Orf virus protein ORFV059 monoclonal antibody hybridoma A3 and monoclonal antibody | |
CN101061136B (en) | Immunity therapeutic preparation with interleukin-2 neutralizing function | |
CN104531730A (en) | Humanized single-chain antibody 8B of clostridium perfringens alpha-toxin | |
CN109206519A (en) | The nano antibody and nucleic acid molecules of a kind of antiurease B subunit and application | |
CN109134611B (en) | Polypeptide for inhibiting EGF (epidermal growth factor receptor) promoting tumor cell proliferation by specifically binding EGFR (epidermal growth factor receptor) | |
CN105985447B (en) | A kind of albumin mating type tumor necrosin relative death inducing ligand variant and its preparation method and application | |
CN102382193B (en) | Fusion protein capable of inducing and activating cancer-targeted T cells, preparation method and use thereof | |
CN101880327A (en) | Scorpion arialgesic anti-tumoral peptide fusion and acquisition method thereof | |
CN107041950A (en) | A kind of Echinococcus moltilocularis polyepitope vaccines LTB AE design, preparation method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201029 Address after: 200237 Shanghai City, Xuhui District City Road 700 Lane 66, Room 201 Patentee after: Sun Jialin Patentee after: Nanjing double bond targeted drug Technology Co., Ltd Address before: 200050 room 55, No. 519, Lane 201, Changning District, Shanghai, Wuyi Road Patentee before: Sun Jialin |